Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.60 |
| ▸ | CDK9 | P50750 | 6/20 | 0.60 |
| ▸ | IGF1R | P08069 | 3/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | PRKACG | P22612 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052850 | 0.84 | FLT3 (0.73) | CCNT1CDK9FLT3MKNK1MKNK2 | |
| SCHEMBL4506765 | 0.81 | FLT3 (0.62) | CCNT1CDK9IGF1RFLT3MKNK1 | |
| SCHEMBL4518219 | 0.80 | RET (0.79) | CDK9IGF1RFLT3MKNK1MKNK2 | |
| SCHEMBL4592600 | 0.79 | CCNT1 (0.57) | CCNT1CDK9IGF1RKCNH2CDK2 | |
| SCHEMBL13588456 | 0.78 | JAK2 (0.67) | CCNT1CDK9IGF1RKCNH2JAK2 | |
| SCHEMBL3048370 | 0.78 | CDK2 (0.59) | CCNT1CDK9IGF1RFLT3EGFR | |
| SCHEMBL4510061 | 0.78 | FLT3 (0.56) | CCNT1CDK9IGF1RFLT3MKNK1 | |
| Hydrochloric Acid SCHEMBL4383810 | 0.78 | JAK2 (0.66) | CCNT1CDK9IGF1RKCNH2JAK2 | |
| SCHEMBL8093455 | 0.78 | JAK2 (0.61) | CCNT1CDK9IGF1REGFRKCNH2 | |
| SCHEMBL4159168 | 0.77 | CDK2 (0.71) | CCNT1CDK9IGF1RFLT3MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | CCNT1 1014/4885CDK9 185/4885IGF1R 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.